Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.0005 USD
Change Today 0.00 / 0.00%
Volume 0.0
IMYN On Other Exchanges
Symbol
Exchange
OTC US
As of 4:30 PM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

immunosyn corp (IMYN) Snapshot

Open
--
Previous Close
$0.0005
Day High
--
Day Low
--
52 Week High
08/19/14 - $0.0020
52 Week Low
12/31/14 - $0.0005
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
$-0.01
Shares Outstanding
267.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNOSYN CORP (IMYN)

Related News

No related news articles were found.

immunosyn corp (IMYN) Related Businessweek News

No Related Businessweek News Found

immunosyn corp (IMYN) Details

Immunosyn Corporation, a development stage company, owns license to market, distribute, and sell a biopharmaceutical drug product, SF-1019 worldwide. SF-1019 is used for the treatment of various diseases and pathological conditions, primarily consisting of chronic inflammatory demyelinating polyneuropathy, diabetic neuropathy, and diabetic ulcers. Immunosyn Corporation also holds license for further improvements of SF-1019 and other compounds, which are developed under the same technology platform and that are chemically similar to SF-1019. The company was founded in 2006 and is headquartered in San Diego, California. Immunosyn Corporation operates as a subsidiary of Argyll Biotechnologies, LLC.

1 Employees
Last Reported Date: 11/19/10
Founded in 2006

immunosyn corp (IMYN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

immunosyn corp (IMYN) Key Developments

SEC Orders Hearings On Registration Suspension Or Revocation Against Immunosyn Corporation For Failure To Make Required Periodic Filings

Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Immunosyn Corporation for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMYN:US $0.00 USD 0.00

IMYN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMYN.
View Industry Companies
 

Industry Analysis

IMYN

Industry Average

Valuation IMYN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOSYN CORP, please visit www.immunosyn.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.